Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 169

The DOI matches its Crossref record.

Controlled Sequential Trials of Carbamazepine in Trigeminal Neuralgia

ROCKLIFF, B. W., DAVIS, E. H.·1966·Archives of Neurology

Abstract

TIC DOULOUREUX is an often incapacitating affliction for which no completely satisfactory medical treatment has been available. While early observations that diphenylhydantoin has beneficial effects have been generally confirmed,1-4results with this drug are variable. Low doses are often ineffective, while the high dosages sometimes required for symptom control are poorly tolerated. Recently, Blom5,6and others7-13have reported that the paroxysmal pain of trigeminal neuralgia is promptly and consistently suppressed by the administration of carbamazepine (Tegretol), an iminostilbene derivative with anticonvulsant activity. Chemically, the compound is 5 carbamyl-5H-dibenz (b,f )-azepine, and, as indicated by the structural formula (Fig 1), it is related to the antidepressant imipramine, but not to the hydantoins. While results with carbamazepine in typical tic douloureux are reported to be highly promising, the benefits observed in postherpetic and atypical facial neuralgias have been minimal. No controlled clinical trials with carbamazepine have been reported.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/archneur.1966.00470140019003

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 169

Metadata

Authors
ROCKLIFF, B. W., & DAVIS, E. H.
Venue
Archives of Neurology
Published
1966-08-01
Volume
15
Issue
2
Pages
129-136
ISSN
0003-9942 (ISSN-L)
OpenAlex
W2078813321
Cited by
169
References
0
FWCI
6.16
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Controlled Sequential Trials of Carbamazepine in Trigeminal Neuralgia. https://app.cochat.ai/papers/10.1001/archneur.1966.00470140019003
The paper
ROCKLIFF, B. W., & DAVIS, E. H. (1966). Controlled Sequential Trials of Carbamazepine in Trigeminal Neuralgia. Archives of Neurology. https://doi.org/10.1001/archneur.1966.00470140019003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.